Latest Regulatory Filings News

NT Minerals Limited reported a net cash outflow of $186,000 for the December quarter, ending with just $2,000 in cash but retaining $1.56 million in undrawn financing facilities.

Dateline Resources Limited’s latest quarterly report reveals a sharp decline in cash reserves, underscoring the company’s urgent need to secure additional funding to sustain its exploration activities.

Cardiex Limited reported a $2.94 million cash outflow for Q2 FY2025 but bolstered its balance sheet with a $3.25 million placement. The company has begun delivering its CONNEQT Pulse units, signaling a new revenue stream and ongoing R&D investment.

Breakthrough Mineral Limited reports a mixed quarterly cash flow with significant exploration expenditure offset by strong financing inflows and plans for reduced corporate costs.

Nagambie Resources Limited reported a tightening cash position in its December 2024 quarter but maintains confidence in ongoing operations backed by over $1 million in available funding.

MCS Services Ltd reports a decline in cash and receivables for Q2 FY2025 while advancing new traffic management contracts and growth initiatives. The company also confirms the collapse of a planned reverse takeover with NJ Ashton Pty Ltd.

Health and Plant Protein Group Limited reported a decline in cash reserves to $0.90 million for Q2 FY25, continuing its efforts to resolve a US tax withholding issue tied to a previous asset sale.

Dreadnought Resources reported a challenging quarter with significant exploration spending and a tight cash position, yet remains confident in its operational outlook and funding prospects.

Culpeo Minerals Limited reported a net cash outflow of $246,000 for the December 2024 quarter but retains robust liquidity with $3.7 million in available funding. The company’s cash position and financing facilities suggest it is well-positioned to continue its exploration activities.

Jindalee Lithium Limited reported a $935,000 net cash outflow for the December 2024 quarter, maintaining a cautious but confident stance on securing future funding to support ongoing exploration activities.

Cleo Diagnostics reports steady progress in its U.S. and Australian clinical trials for an ovarian cancer blood test, maintaining a solid cash reserve of A$7.3 million as it prepares for FDA submission.

Epsilon Healthcare's December 2023 quarterly report reveals significant boardroom conflict and governance breaches, yet operational segments show promising growth.